News
-
-
PRESS RELEASE
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health Inc. announces extension of conditional approval by FDA for Canalevia®-CA1 drug for chemotherapy-induced diarrhea in dogs and seeks partners for NP300 prescription drug for general diarrhea in dogs at Pet Connect conference -
-
-
-
-
-
-
-